Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy

Next Previous
Trial Profile

A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Mesna; Methotrexate; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms Window I

Most Recent Events

  • 05 Jun 2025 Planned End Date changed from 30 Jun 2025 to 30 Jun 2027.
  • 05 Jun 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Jun 2027.
  • 12 Dec 2023 Results assessing Six Years Follow up of Ibrutinib Plus Rituximab Followed By Short Course R-Hyper CVAD/MTX in Patients with Previously Untreated Mantle Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top